US Edition
News from pharmtech.com
We’ve assigned a media bias rating of Center to pharmtech.com. You can read more about our methodology here.
If you want to know if pharmtech.com is credible or reliable, look no further. We rank pharmtech.com as High factuality. Find out more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top pharmtech.com News
Donald Trump · United StatesOn Thursday, Jan. 22, the United States officially announced its withdrawal from the WHO. If you're wondering who's WHO and how it can affect you, let's clear that up for you.See the Story
What is the WHO? How will the U.S. withdrawal affect Hawaiʻi residents?
44% Right coverage: 9 sources
Eli Lilly · GermanyRepertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE:LLY) to develop tolerizing therapies for multiple autoimmune diseases. • Eli Lilly and Co stock is showing positive momentum. Where are LLY shares going? Repertoire Immune is a biotechnology company focused on the discovery and development of programmable T cell-targeted immune medicines. Under the terms of the agreement, Repertoire will receiv…See the Story
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion - Eli Lilly and Co (NYSE:LLY)
87% Center coverage: 8 sources
